AI can't hold a license 🪪, NYP leashes every model 🔗, Med schools ration the scribes 📝
⚡ Around the Wards
The Federation of State Medical Boards says AI is not ready to be licensed like a physician — and its president and board chair published the reasoning, because bills to create a separate licensing lane already came and went in two states this year.
NewYork-Presbyterian put every AI tool it runs under one management system — cancer detection, structural heart, discharge planning, documentation, all governed as one portfolio instead of one purchase at a time.
Medical schools are restricting trainee access to ambient scribes while hospitals sprint to deploy them — the argument is that the struggle of writing the note is the reasoning, and offloading it in year three is different from offloading it in year twelve.
The White House meets OpenAI, Anthropic, Google and Meta today on a government pre-release review framework for frontier models — nobody has yet defined “frontier model” or named which office runs the review.
🎧 Podcast: Health Tech Nerds Radio — “The Grand Roundup” — ProMedica recovered nearly $10 million by using AI to find patients coded as self-pay who actually had billable coverage. The hosts’ sharper point: today’s cash prices look cheap only because that population was priced as bad debt.
🔬 The Big Thing
The people who license every doctor in America just said AI can’t be one. Read what they conceded getting there.
On August 3, Humayun Chaudhry, DO and Christy Valentine Theard, MD, MBA — the president/CEO and board chair of the Federation of State Medical Boards — published their answer to whether generative AI should be licensed to practice medicine.
The answer is no. Not “not yet, pending study” — no, and the reason is not accuracy.
Their argument is that a license isn’t a certificate of competence in the first place. It’s a grant of authority tied to a human being who can be disciplined, sued, and named.
A license was never a statement that you’ll be right. It’s a name to attach when you’re wrong.
That’s the whole thing, and it’s why “the model outperformed physicians on the benchmark” has never been an argument for licensure. Nobody disciplines a checkpoint.
Now the part they conceded.
Bills were introduced this year in Idaho and Iowa to create state licensing boards for “autonomous service providers,” sitting outside the medical board entirely. Both failed.
The authors’ read on that: “We are past the point of wondering whether someone will propose licensing AI like a human physician.” Somebody will do it again, and next time it may not fail.
And Utah has already run the smaller version. The state’s Office of Artificial Intelligence Policy approved a 12-month pilot with Doctronic to automate guideline-based renewals of 192 commonly prescribed drugs under physician oversight — a program that moved through the state’s AI apparatus and then drew the medical board’s attention anyway.
FSMB has now stood up a Workgroup on the Regulation of AI in the Practice of Medicine, because its own 2024 guidance was written before agentic systems existed. They’re also telling boards to go re-read how their state defines “the practice of medicine.”
That last instruction is the one to watch. The definition of “practice of medicine” is the API contract every clinical AI tool is built against, and 69 boards are about to start editing it independently.
💬 Standout Quote
“A medical license, therefore, isn’t just a permit to generate thoughtful and informed answers. It’s a legal and ethical grant of authority tied to human judgment, professional accountability, discipline, transparency, and a duty to put patients first.” — Humayun Chaudhry, DO, and Christy Valentine Theard, MD, MBA
😤 “This is a guild protecting its turf.” Partly, sure. Every profession defends its boundary and this one has a two-hundred-year habit of it. But the argument they made isn’t “we’re better than the machine” — it’s “there has to be someone the patient can name,” and I have not heard a good version of who that is if not the licensee. Tell me the alternative and I’ll take it seriously. “The vendor’s E&O policy” is not the alternative.
😤 “Nobody is seriously trying to license a chatbot as a doctor.” Two state legislatures introduced bills this year. Go read them.
😤 “Fine, but this changes nothing for me tomorrow.” Correct. It changes something for you in about eighteen months, when a board somewhere quietly rewrites the definition of the practice of medicine and your tool is either inside it or outside it. You will not get a comment period notification for that one.
🧪 Try the interactives:
A — A Name to Attach — an animated field of every paid malpractice claim in the NPDB from 2004–2021, settling first into what was alleged and then into what happened to the patient. The FSMB’s argument for why AI can’t hold a license, drawn. Built with real NPDB data.
B — The Accountability Object — 193,023 paid malpractice claims, sorted by what was alleged and what happened to the patient, on one brushable log-log scatter. 1,911,185 reports, 985,019 names, zero models. Explore all 110 cells. Built with real NPDB data.
📡 Builder’s Radar
NewYork-Presbyterian stopped approving AI tools and started managing an AI portfolio
NYP adopted Signal 1’s AI Management System on August 3 to govern everything it runs — cancer and structural heart detection, discharge planning, clinical documentation — through one layer of risk assessment, continuous monitoring, bias detection and audit.
The health system co-designed the platform rather than buying it off a shelf, which is its own signal about how immature this category still is.
The unit of governance just moved from the tool to the portfolio, and that changes what you have to bring to the table.
A single-tool security packet was the old ask. The new ask is: what does your model emit, on what cadence, in what format, so that somebody else’s monitoring layer can watch it drift.
Medical schools are rationing the scribes that hospitals can’t deploy fast enough
Schools and health systems are restricting trainee access to ambient documentation tools even as the same institutions accelerate deployment for attendings, and the reason is developmental, not technical.
“The process of deliberately crafting the note forces us to use our brains to really wrestle with what’s happening,” Yale’s associate dean of educational technology and innovation Jaideep Talwalkar told STAT. “There’s an importance in doing that with great repetition.”
Which means somebody has to build the training-wheels version, and nobody has.
Every ambient scribe on the market is optimized to remove the work. Not one is optimized to make a third-year student produce the note first and then show them what they missed.
😤 “This is just handwriting-versus-typing all over again.” Maybe. The difference is that typing replaced the motor act and this replaces the reasoning act, and we don’t have the study that tells us whether that matters. Nobody does — that’s the actual finding in the piece. Educators are making a call on developmental theory because the evidence isn’t there yet.
The White House sits down with the four labs today, and nobody has defined the noun
The administration meets OpenAI, Anthropic, Google and Meta on August 4 to work on a government-review framework for frontier models before public release, building on the June 2 executive order’s voluntary 30-day pre-launch access system.
Two things are still open: what counts as a “frontier model,” and which office actually runs the review.
If you’re a thin wrapper on a frontier API, a 30-day pre-release review window is a 30-day gap in your release notes.
Two academic centers built an oncology decision tool and are now selling it to you
NYU Langone and Dana-Farber co-developed Solavia, an EHR-embedded oncology decision suite that surfaces biomarker-driven treatment pathways at the point of care. It went live internally at NYU Langone on June 30 and is now commercially available, licensed through NYU’s Technology Opportunities and Ventures office.
Two academic medical centers just decided the distribution model for a clinical pathway tool is a license, not a paper.
That’s the part worth sitting with. The traditional output of an academic clinical-pathways effort is a publication and a slide deck. This one is a SKU.
💡 80/20: If you’re a clinician sitting on an internal tool your department actually uses, find out who runs technology transfer at your institution and ask them one question: what would it take for this to be licensable? Most physicians never ask, and the office exists specifically to answer.
Your buyer may have quietly stopped owning the budget
CIO.com reports that CIOs are increasingly being sidelined on the most strategic AI budgets — by CEOs directly, or by a newly created Chief AI Officer seat that sits outside IT.
This is a general enterprise story, not a health story, which is exactly why it’s worth reading twice.
If you’ve spent six months building a relationship with a health system CIO, there is now a real chance the person who decides your deal doesn’t report to them.
The tell is easy to check: ask whoever you’re talking to who signs, and who else has to say yes. If they hesitate on the second one, you’re mapping the wrong org.
Ultra-shorts
Inocras raised a $31M Series B-3 to bring its CLIA/CAP-certified whole-genome sequencing and automated interpretation platform into US hospital networks, after adoption across 100+ Asian cancer centers. Total funding is now around $100M. The bet is whole-genome as the default instead of narrow NGS panels — which, if it lands, changes the shape of every downstream tool that has to route an incidental finding somewhere.
Labcorp’s 163-gene hereditary risk panel went nationwide direct-to-consumer on August 3, purchasable without a physician order through Labcorp OnDemand with genetic counselors attached and draws at 2,200+ service centers. A large reference lab going self-service on hereditary risk means the results land in primary care inboxes whether or not primary care ordered them.
Nikhil Krishnan wrote up his family’s delivery — emergency C-section, decision-to-delivery under six minutes — and used it to take apart the “shoppable healthcare” premise from the inside. The number that stuck with me, from the Commonwealth Fund data he cites: roughly 40% of all US pregnancy-related deaths occur in the six weeks after delivery — the window where American follow-up is thinnest.
Jordan Shlain, MD went on Graham Walker’s podcast to argue that primary care shouldn’t be tied to insurance at all, after 25 years running a concierge practice. Agree or don’t — the independent-practice thread is worth tracking, because independent physicians are the only buyers in this market who can say yes in one meeting.
💡 BTW
💡 BTW: Christy Valentine Theard — the FSMB board chair who co-wrote today’s Big Thing — is a New Orleans native and med-peds physician who founded her own practice in the New Orleans area, and who, after studying the effects of emotional and physical distress in children, was featured as an expert on The Oprah Winfrey Show on the post-Katrina aftermath. Before she was writing about the accountability structures of medicine, she was on daytime television explaining what a disaster does to a seven-year-old.
📅 Upcoming: EHIgnite Challenge Phase 1 Winners Showcase, Thu Aug 6 — nine teams demo turning dense EHI exports into plain-language output.
What are you building this week? Email and tell me (kevin@clinicians.build) — I read every one.
— Kevin